demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
heparin at therapeutic dose RAPID ...

3 studies excluded by filtering options 0

5679 ATTACC (Houston), 0 010selection pending
5845 ACTIV-4a (heparin), 0 010selection pending
5889 REMAP-CAP Anticoagulation, 0 010selection pending